AbbVie Stock Dividend Comparison and Outlook

AbbVie's dividend history is impressive, with a consistent payout since 2013. The company has raised its dividend payment every year, making it a reliable source of income for investors.

AbbVie's dividend payout ratio has been steadily decreasing over the years, from 74% in 2013 to 43% in 2022. This trend suggests that the company is prioritizing dividend growth over dividend yield.

In 2022, AbbVie paid out $5.6 billion in dividends to its shareholders. This represents a significant portion of the company's net income.

A unique perspective: 2022 Russian Debt Default

AbbVie Inc. (ABBV) has a dividend yield of 3.13%, which means that for every $100 invested in the company's stock, investors would receive $3.13 in dividends per year.

The company pays dividends on a quarterly basis, with the next payment planned for November 14, 2025.

ABBV's annual dividend is $6.56 per share, and the company has increased its dividends for 11 consecutive years. This is a positive sign of the company's financial stability and its ability to pay consistent dividends in the future.

Related reading: Abbv Dividend Increase 2024

ABBV's payout ratio is 301.3%, which is quite high. However, the company's cash flow coverage is reasonable, with a cash payout ratio of 74.2%. This means that the dividend payments are covered by cash flows.

Here's a summary of ABBV's dividend information:

The ex-dividend date for ABBV is October 15, 2025, which means that buyers purchasing shares on or after that date will not be eligible to receive the next dividend payment.

Dividend safety is a crucial aspect to consider when investing in AbbVie stock. A company with a high level of dividend safety is generally considered to have a strong financial position.

Dividend safety refers to a company's ability to continue paying its dividends without interruption or reduction. This is often determined by a company's history of paying dividends and its risk of default.

Assessing dividend safety involves looking at specific indicators, such as AbbVie Inc.'s financial performance and dividend payment history.

Worth a look: Invests in Properties by Paying Delinquent Taxes

Dividend safety is crucial for investors, as it refers to a company's ability to continue paying its dividends without interruption or reduction.

A company with a high level of dividend safety is generally considered to have a strong financial position, with a consistent history of paying dividends and a low risk of default.

Some specific indicators used to assess dividend safety include a company's financial performance and dividend payment history.

Expand your knowledge: Bank Safety Ratings

AbbVie Inc.'s dividend yield is 3.13%, which is higher than 60% of companies in its country.

This information can be found in the percentile ranks table, which allows investors to quickly compare a company's dividend metrics to its peers in the sector, country, and the world.

A dividend yield of 3.13% is also higher than the bottom 25% of dividend payers in the US market, but lower than the top 25% of dividend payers.

Here's a comparison of AbbVie Inc.'s dividend yield to the market:

Note that AbbVie Inc.'s dividend yield is higher than 60% of companies in its country, but its high payout ratio of 215.8% means that its dividend payments are not well covered by earnings.

AbbVie's earnings have been on the rise, with a 4.6% growth in revenue on a constant currency basis in 2024.

The company is expecting this growth to continue, with a 5.7% increase in revenue for 2025.

AbbVie's long-term outlook is solid, with a new guidance for combined sales of immunology drugs Skyrizi and Rinvoq reaching $31 billion by 2027, up from the previous guidance of $27 billion.

This increased guidance suggests that AbbVie's investment in these drugs is paying off, and investors can expect to see continued growth in the years to come.

Explore further: 1 Billion Usd

For investors looking to stay on top of AbbVie's dividend payments, here are some key events to keep in mind.

The company's quarterly dividend payment is scheduled for the 15th of March, 2023, and will be paid out to shareholders on the 31st of March, 2023.

AbbVie has a history of consistently paying its dividend, with 2022 marking the 51st consecutive year of dividend payments.

The company's annual meeting is also worth noting, taking place on the 15th of May, 2023, where shareholders can have their voices heard and stay up-to-date on the company's future plans.

If this caught your attention, see: Cover Corp Shareholders

AbbVie Inc. recently declared a quarterly cash dividend of $1.64 per share, payable to stockholders of record on April 15, 2025.

The dividend will be paid on May 15, 2025, marking another milestone in the company's history of increasing its dividend.

Since its inception in 2013, AbbVie has increased its dividend by a staggering 310 percent.

As a member of the S&P Dividend Aristocrats Index, AbbVie has demonstrated its commitment to providing consistent returns to its investors.

Broaden your view: Kpmg Llp 15 Canada Square London E14 5gl

AbbVie's quarterly cash dividend is payable on May 15, 2025, to stockholders of record at the close of business on April 15, 2025.

The ex-dividend date for AbbVie's stock is October 15, 2025, which means buyers purchasing shares on or after that date will not be eligible to receive the next dividend payment.

The next dividend payment for AbbVie is planned on November 14, 2025, and the company pays dividends on a quarterly basis.

You might enjoy: Next Altcoin to Explode

ABBV's dividend yield is 3.8%, which is higher than the bottom 25% of dividend payers in the US market at 1.4%.

The top 25% of dividend payers in the US market have a dividend yield of 4.5%, which is higher than ABBV's dividend yield.

ABBV's dividend yield is lower compared to the top 25% of dividend payers in the US market.

ABBV's dividend yield is 2.5% lower than the industry average for biotechs.

Here's a comparison of ABBV's dividend yield with other market segments:

ABBV's dividend yield is expected to be 4.1% based on analyst forecasts for up to 3 years.